Quantcast

Latest Migraine surgery Stories

2014-07-09 23:03:50

NobleStitch 1 year results receive positive reviews from physicians at Congenital & Structural Interventions Congress (CSI) in Frankfurt. Fountain Valley, CA (PRWEB) July 09, 2014 Nobles Medical Technologies II (NMT2) today announced that Dr. Michael Mullen (Consultant Cardiologist at the University College Hospital and Member of the NMT2 clinical Advisory Board) presented positive results for the 1-year follow up of patients treated with NobleStitch EL PFO Closure System. NMT2...

2014-06-19 23:18:18

Nobles Medical Technologies II, Inc. (NMT2) today announced that its first Swedish patient Eva has had a successful PFO closure. Fountain Valley, CA (PRWEB) June 19, 2014 Nobles Medical Technologies II, Inc. (NMT2) today announced that its first Swedish patient Eva has had a successful PFO closure. The patient, a nurse/ administrator from the hospital and rehabilitation center in Linkoping, who has suffered from stroke and migraine was being treated with aggressive medication Warfarin (a...

2014-05-16 23:07:41

Nobles Medical Technologies II treats first US patient with NobleStitch EL PFO Closure Device. Fountain Valley, CA (PRWEB) May 16, 2014 Nobles Medical Technologies II (NMT2) today announced that its first American patient has had a successful PFO closure. John Wyall from Orem, Utah has suffered from stroke, aura, and severe chronic fatigue that has worsened in the last few years to the point that he has been bedfast for 14 to 18 hours a day for the last year and a half and unable to do...

2014-04-29 23:07:45

Nobles Medical Technologies II today announced that it has received another Japanese Patent for its NobleStitch Technology. The patent is for the Suturing Devices and Methods for Closing a Patent Foramen Ovale (PFO) and shows the broad coverage of our method and apparatus for PFO Closure expanding to markets around the world. Fountain Valley, CA (PRWEB) April 29, 2014 Ben Brosch, President of NMT2 and co-inventor on the issued patent, commented, “We strive to protect our inventions with...

2014-04-26 23:03:01

Nobles Medical Technologies II, Inc. (NMT2) today announced that it has officially launched sales in Sweden for its NobleStitch EL PFO Closure System. NMT2 launched sales initially in Germany and the UK and will now be expanding this month into Sweden. Fountain Valley, California (PRWEB) April 26, 2014 Following a successful meeting at the Congress of Structural Interventions (CSI) congress in Frankfurt last June NMT2 received significant inquiries to bring its PFO technology to new...

2014-03-12 12:28:44

Episodic migraine patients may soon find relief from innovative medical headband NEW YORK, March 12, 2014 /PRNewswire/ -- CEFALY Technology announced today that its received U.S. Food and Drug Administration (FDA) approval of the Cefaly® medical device for the preventative treatment for migraine headaches. Cefaly® is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the...

Cefaly for migraines
2014-03-12 11:06:45

Brett Smith for redOrbit.com - Your Universe Online In a statement released on Tuesday, the Food and Drug Administration announced the approval of the first-ever medical device made to prevent migraines. Called Cefaly, the device is shaped like a tiara and delivers a “tingling” electric current to the wearer’s forehead. According to a report published in the journal Neurology last month, Cefaly decreased chronic migraine onset by two per month on average, and 38 percent of users...

2014-01-08 08:29:41

The scientific journal "JOURNAL of HEADACHE and PAIN" publishes positive results from a clinical study conducted on 2,313 patients which confirms the high efficacy and safety of the medical device CEFALY ® migraine treatment LIEGE, Belgium, January 8, 2014 /PRNewswire/ -- http://www.thejournalofheadacheandpain.com/content/14/1/95 The efficacy and safety of the CEFALY (R) medical device for migraine treatment had already been reported early 2013 in the scientific journal...

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...

Depression Risk For Migraine Sufferers
2013-10-18 04:25:00

redOrbit Staff & Wire Reports - Your Universe Online People who suffer from migraines are roughly twice as likely to suffer from depression as those who do not experience the chronic, debilitating headaches, according to new research published online in this week’s edition of the journal Depression Research and Treatment. Dr. Esme Fuller-Thomson, Sandra Rotman Endowed Chair of the University of Toronto’s Factor-Inwentash Faculty of Social Work, and her colleagues report that the...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.